CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04788043
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-07-01T00:04:29.742516+00:00
Published At: 2026-06-30T00:00:00+00:00
Record Updated At: 2026-06-30
Results Posted At: 2026-06-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Relapsed Classical Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-30"
protocolSection.identificationModule.nctId: "NCT04788043"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-06-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.